BRPI0515191A - composição farmacêutica, método para aumentar osso ou substituir perda óssea, método para reduzir a dor associada com cicatriz pós-cirúrgica, método para prevenir aderência cirúrgicas, método para aumento ou reparo de pele ou tecido, método para manter volume em fluido ocular durante cirurgia ocular, método para reduzir a dor associada com osteoartrite, método para tratar doença de refluxo gastroesofágico, método para tratar ou prevenir incontinência urinária, método para tratar ou prevenir incontinência fecal, implante método e dispositivo médico - Google Patents

composição farmacêutica, método para aumentar osso ou substituir perda óssea, método para reduzir a dor associada com cicatriz pós-cirúrgica, método para prevenir aderência cirúrgicas, método para aumento ou reparo de pele ou tecido, método para manter volume em fluido ocular durante cirurgia ocular, método para reduzir a dor associada com osteoartrite, método para tratar doença de refluxo gastroesofágico, método para tratar ou prevenir incontinência urinária, método para tratar ou prevenir incontinência fecal, implante método e dispositivo médico

Info

Publication number
BRPI0515191A
BRPI0515191A BRPI0515191-0A BRPI0515191A BRPI0515191A BR PI0515191 A BRPI0515191 A BR PI0515191A BR PI0515191 A BRPI0515191 A BR PI0515191A BR PI0515191 A BRPI0515191 A BR PI0515191A
Authority
BR
Brazil
Prior art keywords
treating
preventing
pain associated
reducing pain
pharmaceutical composition
Prior art date
Application number
BRPI0515191-0A
Other languages
English (en)
Inventor
William L Hunter
David M Gravett
Philip M Toleikis
John K Jackson
Original Assignee
Angiotech Internac Ag
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiotech Internac Ag, Univ British Columbia filed Critical Angiotech Internac Ag
Publication of BRPI0515191A publication Critical patent/BRPI0515191A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIçãO FARMACêUTICA, MéTODO PARA AUMENTAR OSSO OU SUBSTITUIR PERDA óSSEA, MéTODO PARA REDUZIR A DOR ASSOCIADA COM CICATRIZ PóS-CIRúRGICA, MéTODO PARA PREVENIR ADERêNCIAS CIRúRGICAS, MéTODO PARA AUMENTO OU REPARO DE PELE OU TECIDO, MéTODO PARA MANTER VOLUME EM FLUIDO OCULAR DUARNTE CIRURGIA OCULAR, MéTODO PARA REDUZIR A DOR ASSOCIADA COM OSTEOARTRITE, MéTODO PARA TRATAR DOENçA DE REFLUXO GASTROESOFáGICO, MéTODO PARA TRATAR OU PREVENIR INCONTINêNCIA FECAL, IMPLANTE MéDICO E DISPOSITIVO MéDICO. Composições e dispositivos incluindo ácido hialurónico e um composto que inibe a degradação de ácido hialurónico, bem como métodos para manufatura e uso dos mesmos.
BRPI0515191-0A 2004-08-13 2005-08-15 composição farmacêutica, método para aumentar osso ou substituir perda óssea, método para reduzir a dor associada com cicatriz pós-cirúrgica, método para prevenir aderência cirúrgicas, método para aumento ou reparo de pele ou tecido, método para manter volume em fluido ocular durante cirurgia ocular, método para reduzir a dor associada com osteoartrite, método para tratar doença de refluxo gastroesofágico, método para tratar ou prevenir incontinência urinária, método para tratar ou prevenir incontinência fecal, implante método e dispositivo médico BRPI0515191A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60121804P 2004-08-13 2004-08-13
US60121404P 2004-08-13 2004-08-13
PCT/US2005/029177 WO2006020994A2 (en) 2004-08-13 2005-08-15 Compositions and methods using hyaluronic acid and hyluronidase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0515191A true BRPI0515191A (pt) 2008-07-08

Family

ID=35355711

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515191-0A BRPI0515191A (pt) 2004-08-13 2005-08-15 composição farmacêutica, método para aumentar osso ou substituir perda óssea, método para reduzir a dor associada com cicatriz pós-cirúrgica, método para prevenir aderência cirúrgicas, método para aumento ou reparo de pele ou tecido, método para manter volume em fluido ocular durante cirurgia ocular, método para reduzir a dor associada com osteoartrite, método para tratar doença de refluxo gastroesofágico, método para tratar ou prevenir incontinência urinária, método para tratar ou prevenir incontinência fecal, implante método e dispositivo médico

Country Status (7)

Country Link
US (1) US20060040894A1 (pt)
EP (1) EP1781305A2 (pt)
JP (1) JP2008509935A (pt)
AU (1) AU2005272578A1 (pt)
BR (1) BRPI0515191A (pt)
CA (1) CA2577022A1 (pt)
WO (1) WO2006020994A2 (pt)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465766B2 (en) * 2004-01-08 2008-12-16 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US8138265B2 (en) * 2003-01-10 2012-03-20 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US8137688B2 (en) * 2003-01-10 2012-03-20 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
US8802651B2 (en) * 2004-06-30 2014-08-12 Abbott Medical Optics Inc. Hyaluronic acid in the enhancement of lens regeneration
PL1809303T3 (pl) * 2004-09-23 2019-11-29 Arc Medical Devices Inc Kompozycje farmaceutyczne i sposoby dotyczące hamowania zrostów włóknistych lub stanów zapalnych przy użyciu fukanów o niskiej zawartości siarczanów
ITPD20040312A1 (it) * 2004-12-15 2005-03-15 Fidia Advanced Biopolymers Srl Protesi e o supporto per la sostituzione, riparazione, rigenerazione del menisco
WO2006073835A2 (en) * 2004-12-30 2006-07-13 Genzyme Corporation Regiments for intra-articular viscosupplementation
ES2646177T3 (es) * 2006-04-26 2017-12-12 The Regents Of The University Of California Usos terapéuticos de las urolitinas
EP3009477B1 (en) 2006-07-20 2024-01-24 Orbusneich Medical Pte. Ltd Bioabsorbable polymeric composition for a medical device
US20080082170A1 (en) * 2006-09-29 2008-04-03 Peterman Marc M Apparatus and methods for surgical repair
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
US8691321B2 (en) 2006-10-20 2014-04-08 Orbusneich Medical, Inc. Bioabsorbable polymeric composition and medical device background
DE102007003765A1 (de) * 2007-01-19 2008-07-24 Farco-Pharma Gmbh Pharmazeutische Zusammensetzung zur Behandlung von Inkontinenz
US8343536B2 (en) 2007-01-25 2013-01-01 Cook Biotech Incorporated Biofilm-inhibiting medical products
US20100160450A1 (en) * 2007-01-31 2010-06-24 Eric Kuhrts Methods of reducing 15-f2t-isop levels in mammals
WO2008094697A2 (en) * 2007-02-01 2008-08-07 The Trustees Of The University Of Pennsylvania Disc augmentation with hyaluronic acid
EP2155154A2 (fr) * 2007-05-11 2010-02-24 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
WO2008139122A2 (fr) * 2007-05-11 2008-11-20 Galderma Research & Development Preparations pharmaceutiques ou cosmetiques pour application topique et/ou parenterale, leurs procedes de preparation, et leurs utilisations
EP2152743A2 (en) * 2007-05-23 2010-02-17 Allergan, Inc. Cross-linked collagen and uses thereof
DE102007028360B4 (de) * 2007-06-15 2016-04-14 Marcus Asam Wirkstoffkombination für kosmetische Zubereitungen
FR2918276B1 (fr) * 2007-07-02 2010-01-22 Anteis Sa "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
US8318695B2 (en) * 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
FR2919999B1 (fr) * 2007-08-13 2010-01-29 Oreal Compositions d'acide hyaluronique
EP2033689A1 (en) * 2007-08-22 2009-03-11 Italfarmacia S.r.l. Injectable dermatological composition for treatment of the wrinkles
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
WO2009055610A1 (en) * 2007-10-26 2009-04-30 Cytori Therapeutics, Inc. Syringe system for controlled delivery or removal of material
EP2818184B1 (en) 2007-11-16 2018-10-31 Allergan, Inc. Compositions and methods for treating Purpura
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US8394784B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US8394782B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
EP2249891B1 (en) * 2008-02-13 2016-05-25 The Cleveland Clinic Foundation Molecular enhancement of extracellular matrix and methods of use
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
WO2009106641A2 (en) * 2008-02-29 2009-09-03 Coloplast A/S Compositions and methods for augmentation and regeneration of living tissue in a subject
EP2300042A4 (en) * 2008-04-30 2012-05-02 Cleveland Clinic Foundation COMPOSITIONS AND METHODS FOR TREATING URINARY INCONTINENCE
US8652506B2 (en) * 2008-06-05 2014-02-18 Boston Scientific Scimed, Inc. Bio-degradable block co-polymers for controlled release
ITMC20080129A1 (it) * 2008-07-08 2008-10-07 Phitogen Holding S P A Sintesi di acido ialuronico reticolato con inibitore della ialuronidasi microincapsulato.
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
DE102008038368A1 (de) * 2008-08-19 2010-02-25 Biotronik Vi Patent Ag Verwendung von organischen Gold-Komplexen als bioaktive und radioopaque Stentbeschichtung für permanente und degradierbare vaskuläre Implantate
WO2010028025A1 (en) 2008-09-02 2010-03-11 Gurtner Geoffrey C Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
CN102164606B (zh) * 2008-09-30 2014-04-16 电气化学工业株式会社 光稳定化药物组合物
US8263069B2 (en) 2008-12-31 2012-09-11 Johnson Lanny L Compositions including anthocyanin or anthocyanidin for the prevention or treatment of articular cartilage-associated conditions
JP4900848B2 (ja) * 2009-01-26 2012-03-21 宏美 林 人工関節
ITMI20090240A1 (it) * 2009-02-20 2010-08-21 O T I S R L Officine Terapie Inno Vative Composizione comprendente esteri dell'acido caffeico per l'inibizione dell'enzima ialuronidasi umana
US8979821B2 (en) 2009-04-14 2015-03-17 Fezza Family Properties, Llc Lacrimal filler
EP2435083A2 (en) * 2009-05-29 2012-04-04 Galderma Research & Development Combination of adrenergic receptor agonist -1 or -2, preferably brimonidine with fillers, preferablyhyaluronic acid
US20110070204A1 (en) * 2009-09-22 2011-03-24 Ilan Elias Medium for handling and storing biological tissues of the musculoskeletal system outside an organism
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
CA3023725C (en) * 2009-10-22 2021-09-14 Vizuri Health Sciences Llc Methods of producing hydrated flavonoids and use thereof in the preparation of topical compositions
US20110172180A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
AU2015234293B2 (en) * 2010-01-13 2017-04-27 Allergan Industrie Sas Stable hydrogel compositions including additives
US20110171310A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use
US20110171286A1 (en) * 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
WO2011109130A1 (en) * 2010-03-01 2011-09-09 Tautona Group Lp Threads of hyaluronic acid and methods of use thereof
WO2011109129A1 (en) * 2010-03-01 2011-09-09 Tautona Group Lp Threads of cross-linked hyaluronic acid and methods of use thereof
EP2544652A2 (en) * 2010-03-12 2013-01-16 Allergan Industrie SAS A fluid composition comprising a hyaluronan polymer and mannitol for improving skin condition.
EP3520827B1 (en) 2010-03-22 2022-05-25 Allergan, Inc. Cross-linked hydrogels for soft tissue augmentation
GB2480295A (en) * 2010-05-12 2011-11-16 Alan John Waddon Polymeric aqueous composition
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
CN103124558B (zh) * 2010-08-23 2015-06-24 电气化学工业株式会社 交联透明质酸组合物和自交联透明质酸颗粒
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9149422B2 (en) 2011-06-03 2015-10-06 Allergan, Inc. Dermal filler compositions including antioxidants
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
ITAN20110138A1 (it) 2011-10-12 2012-01-11 Regenyal Lab S R L Sintesi di un gel iniettabile multifasico a base di acido ialuronico monofasico libero e reticolato e di acido ialuronico bifasico associato con idrossiapatite con inibitore della ialuronidasi microincapsulato.
JP5772678B2 (ja) * 2012-03-26 2015-09-02 国立大学法人北見工業大学 保水性、吸水性およびヒアルロニダーゼ阻害活性を有する化粧品素材および機能性食品素材
CN103421064A (zh) * 2012-05-21 2013-12-04 中国医学科学院药物研究所 抗脑卒中药物匹诺塞林的两种代谢产物及其合成方法
FR2991876B1 (fr) * 2012-06-13 2014-11-21 Vivacy Lab Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
EP2866813A4 (en) * 2012-06-28 2016-03-02 Salix Pharmaceuticals Ltd METHOD FOR THE CONTINUOUS TREATMENT OF INCONTINENCE USING A FILLER
CN104853742B (zh) * 2012-10-08 2018-11-30 爱普蒂森股份公司 用于治疗用途的基于交联透明质酸和羟基磷灰石的可注射无菌水性制剂
CN102973495A (zh) * 2012-11-15 2013-03-20 上海景峰制药股份有限公司 一种减缓玻璃酸钠在体内降解的方法
ITMI20130075A1 (it) * 2013-01-21 2014-07-22 Altergon Sa Combinazione orale per la prevenzione e il trattamento di patologie vescicali, pelviche e dell¿apparato uro-genitale
KR102016745B1 (ko) * 2013-02-01 2019-09-02 아이진 주식회사 Ｂｍｐ―７ 및 부형제를 포함하는 흉터 형성의 감소 또는 억제용 조성물
US9205105B2 (en) * 2013-05-22 2015-12-08 John Ascencion Campa, Iii Indication and technique for the use of cross-linked hyaluronic acid in the management of pain
WO2015018461A1 (fr) * 2013-08-09 2015-02-12 Genbiotech Compositions therapeutiques comprenant d'acide hyaluronique
US9968623B2 (en) 2013-08-29 2018-05-15 Lanny Leo Johnson Prepackaged sterile syringe or containers with various substance concentrations with or without bioactive reagent
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
FR3020570B1 (fr) * 2014-04-30 2017-07-21 Pierre Fabre Dermo Cosmetique Association d'un acide hyaluronique et d'un polysaccharide sulfate
US9655998B2 (en) * 2014-08-07 2017-05-23 Cook Medical Technologies Llc Encapsulated drug compositions and methods of use thereof
US9180226B1 (en) 2014-08-07 2015-11-10 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US11241520B2 (en) 2014-08-07 2022-02-08 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US9295752B1 (en) * 2014-09-30 2016-03-29 Covidien Lp Bioadhesive for occluding vessels
EP3200838B1 (en) 2014-09-30 2019-09-18 Allergan Industrie, SAS Stable hydrogel compositions including additives
KR102024447B1 (ko) 2015-01-16 2019-11-14 스파인오베이션즈, 인크. 척추 디스크를 치료하기 위한 작용제 및 작용제를 포함하는 의료 키트
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
WO2016128550A1 (en) 2015-02-13 2016-08-18 Allergan Industrie, Sas Implants for sculpting, augmenting or correcting facial features such as the chin
SG10201901426WA (en) * 2015-03-06 2019-03-28 Santen Pharmaceutical Co Ltd Ophthalmic composition
KR101731865B1 (ko) 2015-03-19 2017-05-02 전북대학교산학협력단 조직공학용 생분해성 고분자 지지체와 그 제조방법
JP2017014154A (ja) * 2015-07-01 2017-01-19 公立大学法人岡山県立大学 ウロリチン類を含有するヒアルロン酸産生促進剤
US20180228703A1 (en) 2015-08-08 2018-08-16 Chl Industries, Llc Improved Hyaluronan and Modified-Hyaluronan in Biomedical Applications
EP3357520B1 (en) 2015-09-30 2021-01-06 Jichi Medical University Viscoelastic composition
ES2621877B1 (es) * 2016-01-04 2018-05-04 Agencia Pública Empresarial Sanitaria Hospital De Poniente Solución para resección endoscópica
EP3210572A1 (en) * 2016-02-29 2017-08-30 Elodie Jane Siney Intraocular lens comprising drug-containing microspheres
EP3435975B1 (en) * 2016-04-01 2021-09-15 Boston Scientific Scimed, Inc. Injectable compositions and methods of preparation and use thereof
WO2018020501A1 (en) * 2016-07-27 2018-02-01 Marbelle Threads Ltd. Threads of cross-linked hyaluronic acid and hydroxyapatite
IT201600088648A1 (it) * 2016-08-31 2018-03-03 Alpiflor S R L Composizione nutrizionale o farmaceutica ed integratore alimentare contenente detta compsizione nutrizionale o farmaceutica
IT201600121617A1 (it) * 2016-11-30 2018-05-30 Nekkar Lab Srl Composizione per il trattamento del reflusso gastroesofageo
IT201600121601A1 (it) * 2016-11-30 2018-05-30 Nekkar Lab Srl Composizione orale per il trattamento del reflusso gastroesofageo e del reflusso laringo-faringeo
IT201700124434A1 (it) * 2017-10-31 2019-05-01 Sofar Swiss Sa Compressa da succhiare e/o sciogliere in bocca a base di acido ialuronico e condroitina solfato e loro sali per uso nel trattamento di una sottopopolazione di pazienti GERD.
CN117731600A (zh) * 2018-02-09 2024-03-22 波士顿科学国际有限公司 凝胶组合物及其制备和用途
JP2021155334A (ja) * 2018-05-01 2021-10-07 学校法人近畿大学 中分子ヘパリンまたは中分子ヘパリンのアミノ酸誘導体を含む医薬組成物
WO2019230626A1 (ja) 2018-05-28 2019-12-05 花王株式会社 夜間頻尿の予防又は改善剤
EP3920852B1 (en) * 2019-02-09 2025-04-09 Theracell, LLC Demineralized bone fiber implant compositions and their methods of fabrication
KR102321658B1 (ko) * 2019-12-06 2021-11-03 영산대학교산학협력단 로즈마리 추출물을 포함하는 임플란트 표면 코팅용 조성물
KR102344959B1 (ko) * 2019-12-06 2021-12-28 영산대학교산학협력단 로즈마리 추출물을 포함하는 임플란트의 골유착 개선용 조성물
CN111012953B (zh) * 2019-12-10 2022-03-29 华熙生物科技股份有限公司 一种抗酶解交联透明质酸凝胶的制备方法及所得产品和应用
EP3854377A1 (fr) * 2020-01-22 2021-07-28 Laboratoires Genevrier Sas Composition comprenant de l'acide hyaluronique et un polyol ou de carboxyméthylcellulose
IT202000022477A1 (it) * 2020-09-23 2022-03-23 Sofar Swiss Sa Composizioni comprendenti una condroitina vegetale o un suo analogo e loro uso nel trattamento disturbi della mucosa del tratto orale, faringo-laringeo e/o gastro-esofageo
JP7628908B2 (ja) * 2021-07-15 2025-02-12 日清食品ホールディングス株式会社 ヒアルロン酸産生促進剤
CN114028610B (zh) * 2021-10-26 2022-10-25 北京诺康达医药科技股份有限公司 一种亲水性注射型皮肤填充组合物及其制备方法与应用
CN114699554A (zh) * 2021-12-20 2022-07-05 南京思元医疗技术有限公司 一种用于医疗美容的纠正皮肤皱纹注射液及其制备方法
US12102556B2 (en) * 2022-05-31 2024-10-01 Max Azevedo System and method for fallopian birth control
CN115252893B (zh) * 2022-08-26 2023-04-25 上海市第十人民医院 一种抗炎抗氧化性神经导管的制备
CN115487171A (zh) * 2022-11-10 2022-12-20 郑州大学 一种透明质酸-异甘草素偶联物、溶解型微针贴及制备方法和应用
KR20260021016A (ko) 2023-06-02 2026-02-12 33 메디칼, 인크. 추간판성 통증의 치료를 위한 조성물, 및 그의 제조 및 사용 방법
WO2024254456A1 (en) * 2023-06-07 2024-12-12 Pmidg, Llc Point of use device coating
JP2025041170A (ja) * 2023-09-13 2025-03-26 昌毅 本田 肛門狭窄化治療法
TR2024005209A2 (tr) * 2024-04-30 2024-05-21 Vsy Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi Bi̇lhassa i̇ntersti̇syel si̇sti̇t hastaliğinin tedavi̇si̇ i̇çi̇n bi̇r formülasyon
CN119708555B (zh) * 2025-02-28 2025-05-13 成都丁因生物科技有限公司 一种双重修饰的交联透明质酸凝胶制备方法及应用
CN120789281B (zh) * 2025-09-12 2025-11-25 温州医科大学附属第一医院 一种桑色素纳米颗粒、pH响应性水凝胶及应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438253A (en) * 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
GB8504025D0 (en) * 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
US4746504A (en) * 1986-03-14 1988-05-24 Bio-Technology General Corp. Heavy metal salts of hyaluronic acid and their use as antimicrobial agents
US5916880A (en) * 1987-12-21 1999-06-29 Bukh Meditec A/S Reduction of skin wrinkling using sulphated sugars
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US5527779A (en) * 1988-03-23 1996-06-18 Top Gold Pty Limited Topically applied gold organic complex
US5356883A (en) * 1989-08-01 1994-10-18 Research Foundation Of State University Of N.Y. Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US6440427B1 (en) * 1991-06-17 2002-08-27 Biovitrum Ab Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
US5358883A (en) * 1992-02-03 1994-10-25 Motorola, Inc. Lateral bipolar transistor
US6218373B1 (en) * 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5942498A (en) * 1992-02-20 1999-08-24 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
US5612321A (en) * 1995-06-22 1997-03-18 Hercules Incorporated Antioxidant grafted polysaccharides
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
DK2111876T3 (da) * 1995-12-18 2011-12-12 Angiodevice Internat Gmbh Tværbundne polymerpræparater og fremgangsmåder til anvendelse deraf
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
EP1162984A2 (en) * 1999-03-15 2001-12-19 Trustees Of Boston University Use of cross linked polysaccharides for the inhibition of angiogenesis
US20040043047A1 (en) * 1999-03-26 2004-03-04 Parfums Christian Dior Cosmetic or dermatological compositions containing at least one substance for increasing the functionality and/or expression of the CD44 membrane receptors of skin cells
US6312725B1 (en) * 1999-04-16 2001-11-06 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition
JP5089006B2 (ja) * 2000-06-29 2012-12-05 ピラマル ヘルスケア （カナダ） リミテッド 軟骨および他の組織の修復および再生のための組成物および方法
AU2001265400A1 (en) * 2000-07-28 2002-02-13 Anika Therapeutics, Inc. Bioabsorbable composites of derivatized hyaluronic acid
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
WO2003000190A2 (en) * 2001-06-25 2003-01-03 Depuy Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
CA2451248A1 (en) * 2001-06-25 2003-01-03 Depuy International Limited Composition comprising glycosaminoglycans and hyaluronidase inhibitors for the treatment of arthritic joints
EP1465596A1 (en) * 2002-01-18 2004-10-13 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
ITPD20020064A1 (it) * 2002-03-12 2003-09-12 Fidia Advanced Biopolymers Srl Derivati esterei dell'acido ialuronico per la preparazione di idrogelda utilizzare in campo biomedico, sanitario e chirurgico e come sistem
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US6682904B1 (en) * 2002-08-15 2004-01-27 Deliatroph Pharmaceuticals, Inc. Specific inhibitors of hyaluronidase 2, and methods of identifying and using same
US20050181977A1 (en) * 2003-11-10 2005-08-18 Angiotech International Ag Medical implants and anti-scarring agents
EP1687041A2 (en) * 2003-11-20 2006-08-09 Angiotech International AG Soft tissue implants and anti-scarring agents
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US20050209664A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Electrical devices and anti-scarring agents

Also Published As

Publication number Publication date
US20060040894A1 (en) 2006-02-23
EP1781305A2 (en) 2007-05-09
WO2006020994A2 (en) 2006-02-23
AU2005272578A1 (en) 2006-02-23
WO2006020994A3 (en) 2006-07-20
JP2008509935A (ja) 2008-04-03
CA2577022A1 (en) 2006-02-23

Similar Documents

Publication Publication Date Title
BRPI0515191A (pt) composição farmacêutica, método para aumentar osso ou substituir perda óssea, método para reduzir a dor associada com cicatriz pós-cirúrgica, método para prevenir aderência cirúrgicas, método para aumento ou reparo de pele ou tecido, método para manter volume em fluido ocular durante cirurgia ocular, método para reduzir a dor associada com osteoartrite, método para tratar doença de refluxo gastroesofágico, método para tratar ou prevenir incontinência urinária, método para tratar ou prevenir incontinência fecal, implante método e dispositivo médico
Conrad et al. A 6-year experience with the use of expanded polytetrafluoroethylene in rhinoplasty
BRPI0512604A (pt) terapia de drogas em combinação para reduzir a formação de tecido de cicatrização
BRPI0519285B8 (pt) método para produzir um biomaterial implantável resistente a calcificação, biomaterial implantável resistente a calcificação, dispositivo biológico implantável, implante biocompatível, kit para reparar uma lesão de tecido, curativo de ferimentos
MXPA03003906A (es) Dispositivos de implante quirurgicos que tienen tejido de cicatriz reducida.
WO2009045912A3 (en) Vertebrally-mounted tissue retractor and method for use in spinal surgery
WO2005055958A3 (en) Improved surgical adhesive and uses therefor
WO2008027371A3 (en) Low profile bioactive agent delivery device
RU2016110605A (ru) Способ получения инъекционного гидрогеля на основе гиалуроновой кислоты, содержащего лидокаин и щелочной агент, стерилизованного теплом
WO2004010854A3 (en) Apparatus and method for preventing adhesions between an implant and surrounding tissues
BRPI0712194A2 (pt) Implantes pélvico e cirúrgico combinação ferramenta cirúrgica útil para implantar um implante pélvico métodos de tratamento de uma condição pélvica, e de prolapso vaginal, e, método para manipular um implante cirúrgico
WO2007120539A3 (en) Orthopedic device
WO2008088645A3 (en) Trans urinary bladder access device and method
WO2011065979A3 (en) Adhesive delivery devices, systems and methods
WO2007100459A3 (en) Surgical slings
BRPI0419111A (pt) dispositivo de implante no osso revestido com ácido hialurÈnico
WO2008079400A3 (en) Surgical applications for bmp binding protein
Mendelsohn et al. Gore-tex augmentation grafting in rhinoplasty--is it safe?
RU2017103186A (ru) Стерилизованная термогелевая композиция
Sadeghi-Nejad et al. Penile prosthesis surgery in the management of erectile dysfunction
MX2009002260A (es) Cateter o desviacion implantable que permite el suministro gradual de agentes terapeuticos.
WO2006123226A3 (en) An inhibitor of mtor for inhibiting the formation of scar tissue
RU2353319C1 (ru) Способ аутопластики сухожилия дистального разгибателя пальца кисти
Lo et al. Immediate autologous fat graft augmentation rhinoplasty after removal of extruding or infected silicone implant.
RU2480168C1 (ru) Способ герниопластики ущемленных паховых грыж

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]